Zyrtec

Influenza, House Dust Mite Allergy, Chronic Urticaria + 8 more
Treatment
14 FDA approvals
20 Active Studies for Zyrtec

What is Zyrtec

CetirizineThe Generic name of this drug
Treatment SummaryCetirizine (also known as Zyrtec) is a medication used to treat common allergic symptoms such as sneezing, coughing, nasal congestion, and hives. It is particularly effective in treating allergic rhinitis, an allergy that affects 15-30% of people in the United States. Cetirizine is one of the first non-sedating antihistamines that can be taken to manage symptoms.
12 Hour Allergy Dis the brand name
image of different drug pills on a surface
Zyrtec Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
12 Hour Allergy D
Cetirizine
1988
805

Approved as Treatment by the FDA

Cetirizine, otherwise called 12 Hour Allergy D, is approved by the FDA for 14 uses including Hay Fever and Rhinitis, Allergic .
Hay Fever
Rhinitis, Allergic
Rhinitis, Allergic
Used to treat Respiratory Allergy in combination with Pseudoephedrine
Chronic Urticaria
Grass Allergy
Respiratory Allergy
Used to treat Respiratory Allergy in combination with Pseudoephedrine
Allergy to Tree Pollen
Used to treat Allergy to Tree Pollen in combination with Pseudoephedrine
Chronic Idiopathic Urticaria
Seasonal Allergic Rhinitis
Perennial Allergic Rhinitis (PAR)
Ragweed Allergy
House Dust Mite Allergy
Allergy to Mold
Allergy to Animal Dander

Effectiveness

How Zyrtec Affects PatientsCetirizine is a medication that helps reduce or get rid of symptoms such as chronic hives, seasonal or year-round allergies, asthma, and atopic dermatitis. Studies have found it to be an effective treatment for respiratory diseases, and it also has anti-inflammatory effects. It can start to improve symptoms of hives within 20 minutes of taking it, and the effects can last up to 24 hours. Additionally, taking cetirizine can help reduce the need for topical anti-inflammatory creams used to treat atopic dermatitis.
How Zyrtec works in the bodyCetirizine is a drug that blocks the effects of histamine in the body. It works by blocking histamine receptors in the body, which prevents histamine from performing its normal activities. In clinical studies, side effects such as dry mouth were more common with cetirizine than with a placebo. Studies have also shown that cetirizine does not penetrate the brain when taken systemically, meaning it has no significant effect on brain receptors.

When to interrupt dosage

The suggested dosage of Zyrtec is contingent upon the diagnosed condition, such as Chronic Idiopathic Urticaria, Allergy to Tree Pollen and Allergy; Dander. The quantity of dosage is contingent upon the technique of delivery (e.g. Oral or Syrup) delineated in the table below.
Condition
Dosage
Administration
Allergy to Animal Dander
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous
Grass Allergy
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous
Rhinitis, Allergic
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous
Influenza
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous
Ragweed Allergy
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous
Allergy to Mold
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous
House Dust Mite Allergy
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous
Chronic Urticaria
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous
Hay Fever
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous
Rhinitis, Allergic
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous
Allergy to Tree Pollen
, 5.0 mg/mL, 10.0 mg, 5.0 mg, 1.0 mg/mL, 1.0 mg, 20.0 mg, 2.4 mg/mL, 10.0 mg/mL, 2.5 mg
, Oral, Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Syrup, Syrup - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Ophthalmic, Suspension, Suspension - Oral, Solution / drops, Solution / drops - Ophthalmic, Injection, Injection - Intravenous, Intravenous

Warnings

Zyrtec Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Cetirizine may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Cetirizine may interact with Pulse Frequency
There are 20 known major drug interactions with Zyrtec.
Common Zyrtec Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Hydroxyzine.
Mobocertinib
Major
The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Mobocertinib.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Cetirizine is combined with Oliceridine.
Zyrtec Toxicity & Overdose RiskThe toxic dose of cetirizine for rats is 365mg/kg when taken orally, and 138mg/kg when injected. The toxic dose of cetirizine for mice is 50mg/kg when taken orally and 0.1mg/kg when taken orally. In mice, cetirizine did not cause cancer at doses up to 20mg/kg. However, in male mice, there was an increase in benign liver tumors at 16mg/kg. Cetirizine did not cause mutations, and did not affect fertility in mice at doses up to 64mg/kg. Cetir
image of a doctor in a lab doing drug, clinical research

Zyrtec Novel Uses: Which Conditions Have a Clinical Trial Featuring Zyrtec?

38 active clinical trials are currently examining the potential of Zyrtec to provide relief from Chronic Idiopathic Urticaria, Mold Allergy and Grass Allergy.
Condition
Clinical Trials
Trial Phases
Influenza
29 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3
Rhinitis, Allergic
0 Actively Recruiting
Allergy to Animal Dander
0 Actively Recruiting
Grass Allergy
0 Actively Recruiting
Allergy to Tree Pollen
0 Actively Recruiting
Chronic Urticaria
0 Actively Recruiting
House Dust Mite Allergy
0 Actively Recruiting
Ragweed Allergy
0 Actively Recruiting
Allergy to Mold
0 Actively Recruiting
Rhinitis, Allergic
0 Actively Recruiting
Hay Fever
0 Actively Recruiting

Zyrtec Reviews: What are patients saying about Zyrtec?

5Patient Review
5/9/2022
Zyrtec for Non-Seasonal Allergic Runny Nose
I suffer from seasonal allergies and Zyrtec has been a godsend. It doesn't make me drowsy like some other medications, and I haven't experienced any adverse effects.
5Patient Review
5/9/2022
Zyrtec for Non-Seasonal Allergic Runny Nose
Zyrtec has been really helpful for me in managing my seasonal allergies. It doesn't make me drowsy, and I haven't experienced any negative side effects.
3Patient Review
8/21/2019
Zyrtec for Seasonal Runny Nose
I was pleased to find an allergy medication that worked for me; however, I began experiencing severe joint pain and started gaining weight uncontrollably. Additionally, I developed a horrible itch all over my body that wouldn't stop. Needless to say, I won't be taking this again.
3Patient Review
2/7/2022
Zyrtec for Non-Seasonal Allergic Runny Nose
My child had been taking this daily for 2 years. It had helped with his allergies BUT it also caused side effects such as anxiety, depression and intrusive thoughts. He was a mental mess thanks to this drug.
3Patient Review
8/21/2019
Zyrtec for Seasonal Runny Nose
Though this did alleviate my allergies, I found the joint pain it caused to be unbearable. I also gained 25 pounds while on this medication, and started having nightmares. The incessant itchiness was just too much for me to handle.
3Patient Review
2/7/2022
Zyrtec for Non-Seasonal Allergic Runny Nose
My child had been taking this daily for 2 years. It had helped with his allergies BUT it also caused side effects such as anxiety, depression and intrusive thoughts. He was a mental mess thanks to this drug.
2.7Patient Review
4/19/2022
Zyrtec for Seasonal Runny Nose
Though this medication did clear my sinuses, I experienced some pretty uncomfortable side effects. The next day I had heart palpitations and felt dizzy and down. Overall, not worth it.
2.7Patient Review
4/19/2022
Zyrtec for Seasonal Runny Nose
I took one of these at about 5 pm. My nose was cleared by 8, but I woke up the next day with regular heart palpitations and they lasted the entire day! I also had some dizziness and a depressed mood. Won't take again.
2Patient Review
7/11/2022
Zyrtec for Allergic Conjunctivitis
I ended up with Fixed Drug Eruption as a result of this treatment. Many areas of my body became pigmented, and I didn't understand what was happening at first because there were no warnings about this side effect anywhere.
2Patient Review
7/11/2022
Zyrtec for Allergic Conjunctivitis
Unfortunately, this caused me to develop Fixed Drug Eruption. Many areas of my body became pigmented and I didn't understand what was happening at first because there were no mention of such side effects anywhere.
1.3Patient Review
8/20/2021
Zyrtec for Hives
I tried this over-the-counter medication because of a tick bite and was prescribed it by my doctor. I took it for 35 days before trying to wean myself off, but now whenever I don't take it, I break out in hives. Additionally, I've been experiencing itching, burning skin, headaches, and the sensation that something is crawling on me. Going cold turkey has been awful so far.
1.3Patient Review
8/20/2021
Zyrtec for Hives
I used this medication as directed by my doctor, and it's been an awful experience. I'm now trying to wean myself off of the drug, but the withdrawal symptoms are terrible. Itchy skin, burning sensation, headaches...I wouldn't wish this on anyone.
1Patient Review
3/20/2019
Zyrtec for Seasonal Runny Nose
After reading more about the potential side effects of this medication, I stopped taking it after only two pills. It's concerning that companies can put products on the market for over-the-counter use without fully testing them first.
1Patient Review
6/13/2020
Zyrtec for Seasonal Runny Nose
After taking Zyrtec for a while, I woke up with yellow eyes. This is apparently a sign of liver damage from the drug. Needless to say, I won't be taking it again.
1Patient Review
3/20/2019
Zyrtec for Seasonal Runny Nose
After doing more research on this medication, I stopped taking it after only two pills. I was really shocked that companies are allowed to sell products like this over the counter without people knowing about the potential side effects!
1Patient Review
6/13/2020
Zyrtec for Seasonal Runny Nose
Zyrtec never really helped me that much, and now I know why. It turns out that this medication can cause some pretty severe liver problems, including jaundice. Needless to say, I'll be looking for a different way to keep my allergies at bay from now on.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zyrtec

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What's difference between Claritin and Zyrtec?

"Zyrtec includes cetirizine hydrochloride, which is also referred to as cetirizine HCL. Meanwhile, Claritin has loratadine. Zyrtec and Claritin are second-generation antihistamines, which means they are less likely to make a person feel drowsy or have any other effects on alertness compared to older, first-generation antihistamines."

Answered by AI

What exactly does Zyrtec do?

"The drug cetirizine is an antihistamine used to relieve symptoms of allergies such as watery eyes, a runny nose, itchy eyes/nose, sneezing, hives, and itching. By blocking the natural substance histamine, which is produced by the body during an allergic reaction, it is effective in treating these symptoms."

Answered by AI

Does Zyrtec make you sleepy?

"Zyrtec can make some people sleepy, but not everyone. Try taking it for the first time when you're at home and won't have to operate heavy machinery, just in case. Claritin is less likely to cause sleepiness at recommended doses."

Answered by AI

Is Zyrtec OK to take everyday?

"What are some frequently asked questions about cetirizine?

Is it safe to take cetirizine every day?

Yes, cetirizine is safe to take every day if you have allergy symptoms on a daily basis. If you don't have allergy symptoms every day, you can take it as needed on days when these symptoms bother you."

Answered by AI

Clinical Trials for Zyrtec

Image of National Institutes of Health Clinical Center in Bethesda, United States.

BPL-1357 for Flu

18 - 55
All Sexes
Bethesda, MD
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital.
Phase 2
Waitlist Available
National Institutes of Health Clinical Center (+1 Sites)Luca T Giurgea, M.D.
Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+
All Sexes
Nashville, TN
This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?
Phase 2
Recruiting
Vanderbilt University Medical CenterNatahsa Halasa, MD, MPH
Image of Altasciences Inc - Kansas City in Overland Park, United States.

VNT-101 for Safety and Tolerability Study

18 - 59
All Sexes
Overland Park, KS
A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years. Part 1 Single Ascending Dose (SAD) will enroll 48 participants into six cohorts (S1-S6) to receive single oral doses of VNT-101 (100-1500 mg) or placebo under fasting or fed (S5 only) conditions. Part 2 Multiple Ascending Dose (MAD) will enroll 30 participants into three cohorts (M1-M3) to receive multiple oral doses of VNT-101 (250-750 mg BID Days 1-5, QD Day 6) or placebo under fasting conditions. Dose escalation in both parts will proceed after Protocol Safety Review Team (PSRT) review. The primary objective for Part 1 is to evaluate the safety and tolerability of single ascending oral (SAD) doses of VNT-101 in healthy adult participants under either fasting or fed conditions. The primary objective for part 2 is to evaluate the safety and tolerability of multiple ascending oral (MAD) doses of VNT-101 in healthy adult participants.
Phase 1
Recruiting
Altasciences Inc - Kansas City
Have you considered Zyrtec clinical trials? We made a collection of clinical trials featuring Zyrtec, we think they might fit your search criteria.Go to Trials
Image of Saint Louis University Center for Vaccine Development in St Louis, United States.

A/Texas for Flu

18 - 45
All Sexes
St Louis, MO
This is a research study to understand what happens when a person is infected with influenza ("flu") and how the body controls the infection. Healthy participants (challenge) will be infected with a strain of flu (H3N2), and followed to see what symptoms occur and when they occur. Blood will be drawn and nasopharyngeal (NP) swabs will be collected before participants are infected to understand if having antibodies can protect participants from flu infection or lead to a milder flu illness. Blood will also be drawn and NP swabs collected after participants are infected to understand how and when the body's immune response to flu occurs. Participants will also breathe through a device for virus collection every other day. Participants will be screened during one or more visits and will stay in the inpatient challenge unit for at least 10 days, maybe longer. Participants will complete a FLU PRO Diary Card daily. Blood will be drawn before the challenge and on Days 2, 4, and 8 while in the inpatient unit. NP samples will be taken every day to check for viruses and on certain days, immune responses such as antibodies. If on Day 8 (7 days after the challenge) the participant still has flu virus, medicine will be offered to treat the flu and the participant will be asked to stay in the challenge unit until NP swabs are negative for 2 consecutive days. Once the participant is discharged from the challenge unit, they will be asked to return to the clinic for 3 more visits. At the end of the study will be a final phone call.
Phase 1
Waitlist Available
Saint Louis University Center for Vaccine DevelopmentDaniel F. Hoft, MD, PhD
Image of Emory University Hospital Clinical Research Network in Atlanta, United States.

Influenza Virus for Influenza

18 - 49
All Sexes
Atlanta, GA
This study is designed to help us better understand how the immune system responds to the flu and how flu is transmitted in the environment. The ultimate goal is to develop better vaccines and drugs to protect against or fight the flu. This study will describe how the body's immune system responds to the flu virus during and after infection and how the flu virus is transmitted in the environment. The study will use a flu virus called A/Texas/71/2017 (H3N2), clade 3C3a produced specifically for clinical research in controlled conditions. The study will also assess the safety of the H3N2 influenza challenge in healthy participants. Mild to moderate symptoms are expected based on previous studies with this strain of influenza. Study volunteers will be recruited and screened from the general population of metro Atlanta through advertisements or identified from a database of research participants who have previously agreed to be contacted for future research studies. Participants will provide written consent before study participation. Up to 200 healthy adults, 18-49 years old, will be screened for participation. Eligible participants will take part in the study over 5 months. Enrolled participants will be admitted to Emory University Hospital during which time they will receive the influenza virus in the form of a spray in the nose or exposure to infected participants followed by an 8-12 day inpatient stay for observation. Follow-up outpatient visits will take place at the Hope Clinic of the Emory Vaccine Center. Participants will receive compensation (pro-rated for all visits completed) for their time and effort. There will be no costs to participants as a result of being in the study.
Phase 1
Recruiting
Emory University Hospital Clinical Research Network (+1 Sites)Nadine Rouphael, MD
Have you considered Zyrtec clinical trials? We made a collection of clinical trials featuring Zyrtec, we think they might fit your search criteria.Go to Trials
Image of Loma Linda University Medical Center Troesh Medical Campus in Loma Linda, United States.

Endotracheal Suctioning for Procedural Pain

18+
All Sexes
Loma Linda, CA
The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress. The main questions this study aims to answer are: Does ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress. Participants will: Have pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning. Provide demographic information (like age, gender, and diagnosis) from medical records. This research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.
Recruiting
Has No Placebo
Loma Linda University Medical Center Troesh Medical CampusElizabeth Johnston Taylor, PhD, FAAN
Image of Research Institute of McGill University Health Centre in Montréal, Canada.

COVID-19 Booster + Flu Vaccine for Immunocompromised People

18+
All Sexes
Montréal, Canada
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose non-inferior in inducing a 1-month peak protective humoral response against COVID-19, compared to a strategy of sequential administration of COVID-19 booster dose followed by seasonal IIV given one month later? 2. Is the administration of the most up-to-date recommended COVID-19 booster doses at 3-month intervals superior at maintaining a longer term protective humoral immune response, compared to booster doses administered at 6-month intervals? Researchers will compare (1) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 3-month interval, (2) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 3-month interval, (3) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 6-month interval, and (4) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 6-month interval to see if median neutralization capacity of patient sera is non-inferior in the co- vs. sequential administration arms at 1-month after the initial COVID-19 booster and superior in the 3-month interval arms vs. the 6-month interval arms at 12 months after the initial COVID-19 booster. These outcomes will also be compared at 2-months for question 1 and 6-months for question 2. People living with immunocompromising conditions who take part in the trial will have blood samples drawn to verify immune response, be monitored for changes in clinical events and therapies, and complete questionnaires to verify adverse effects, quality of life and economic impact.
Phase 2
Recruiting
Research Institute of McGill University Health Centre (+1 Sites)
Image of Kaiser Permanente Northern California in Pleasanton, United States.

Nudge Communication for Flu Vaccination

18+
All Sexes
Pleasanton, CA
In randomized clinical trials and observational studies, influenza vaccination is effective in reducing influenza-related illness and hospitalizations and potentially cardiovascular (CV) events and mortality in select populations. However, the potential population-level benefit of influenza vaccination is limited by its uptake. Novel implementation strategies to improve vaccination uptake are needed. KP VACCINATE is a multicenter, sequential, individual-level randomized controlled implementation trial examining the effectiveness of a CV-focused nudging communication vs. usual care communication on influenza vaccination uptake among Kaiser Permanente Northern California (KPNC) and Kaiser Permanente Mid Atlantic States (KPMAS) eligible members during the 2024-2025 influenza season.
Waitlist Available
Has No Placebo
Kaiser Permanente Northern California (+1 Sites)Ankeet Bhatt, MD
Have you considered Zyrtec clinical trials? We made a collection of clinical trials featuring Zyrtec, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security